PATENT CLAIM ANALYSIS

Application Number: 15896400
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["552", "553000"]

Abstract:
The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Claim (Index 13):
The method according to  claim 9 , wherein the metabolic disease is selected from the group consisting of insulin resistance, Type I and Type II diabetes, and obesity.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 88.0
- Lexical Diversity: 1.29412
- Patent Class: 552.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15724919', '15793554', '15597423', '15597431', '15439303']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7515121768941425
- 35 USC 102 Novelty (BERT): 0.5936694957334548
- Combined Prediction Score: 0.7357279087780737
- Mean Citation Score: 318.1284100000001
- Max Citation Score: 336.9179
- Similarity Product: 229.07019588282705

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test